People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care.
Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.
Health and social care professionals should follow our general guidelines for people delivering care:
Definitions of depression and severity
Depression refers to a wide range of mental health problems characterised by the absence of a positive affect (a loss of interest and enjoyment in ordinary things and experiences), low mood and a range of associated emotional, cognitive, physical and behavioural symptoms. For more detail, see the International Classification of Diseases-11 (ICD-11) or the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria for depression.
Depression severity exists along a continuum and is essentially composed of 3 elements:
symptoms (which may vary in frequency and intensity)
duration of the disorder
the impact on personal and social functioning.
Severity of depression is therefore a consequence of the contribution of all of these elements.
Traditionally, depression severity has been grouped under 4 categories (subthreshold, mild, moderate and severe) but in the development of this guideline the committee wanted to develop a way of representing the severity of depression which best represents the available evidence on the classification and would help the uptake of the recommendations in routine clinical practice. This guideline has therefore defined new episodes of depression as less severe or more severe depression.
Less severe depression encompasses subthreshold and mild depression, and more severe depression encompasses moderate and severe depression. Thresholds on validated scales were used in this guideline as an indicator of severity. For example, a score 16 on the PHQ-9 scale was used, with scores less than 16 defined as less severe depression, and scores of 16 or more defined as more severe depression.
When working with people with depression and their families or carers, ensure steps are taken to reduce stigma, discrimination and barriers for individuals seeking help for depression (for example, reducing judgemental attitudes, showing compassion, parity of esteem between mental illness and physical illness, treating people as individuals). [2009, amended 2022]
Provide people with depression with up-to-date and evidence-based verbal and written information about depression and its treatment, appropriate to their language, cultural and communication needs.
Consider developing advance decisions about treatment choices (including declining treatment) and advance statements collaboratively with people who have recurrent severe depression or depression with psychotic symptoms, and for those who had treatment under the Mental Health Act 2007, in line with the Mental Capacity Act 2005, and review them regularly. Record the decisions and statements and include copies in the person's care plan in primary and secondary care, and give copies to the person and to their family or carer, if the person agrees. [2009, amended 2022]
Advise people with depression that they can set up a Health and Welfare Lasting Power of Attorney, and support them to do so if appropriate, so that a trusted person can represent their interests and make decisions on their behalf if they do not have the capacity to make decisions themselves at any point. [2022]
Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression if:
During the last month, have they often been bothered by feeling down, depressed or hopeless?
During the last month, have they often been bothered by having little interest or pleasure in doing things?
See also the NICE guideline on depression in adults with a chronic physical health problem. [2009, amended 2022]
If a person answers 'yes' to either of the depression identification questions (see recommendation 1.2.1) but the practitioner is not competent to perform a mental health assessment, refer the person to an appropriate professional who can. If this professional is not the person's GP, inform the person's GP about the referral. [2009]
If a person answers 'yes' to either of the depression identification questions (see recommendation 1.2.1) and the practitioner is competent to perform a mental health assessment, review the person's mental state and associated functional, interpersonal and social difficulties. [2009]
Consider using a validated measure (for example, for symptoms, functions and/or disability) when assessing a person with suspected depression to inform and evaluate treatment. [2009]
If a person has language or communication difficulties (for example, sensory or cognitive impairments or autism), to help identify possible depression consider:
asking the person about their symptoms directly, using an appropriate method of communication depending on the person's needs (for example, using a British Sign Language interpreter, English interpreter, or augmentative and alternative communication)
asking a family member or carer about the person's symptoms.
See also the NICE guidelines on mental health problems in people with learning disabilities and autism spectrum disorder. [2009, amended 2022]
Conduct a comprehensive assessment that does not rely simply on a symptom count when assessing a person who may have depression, but also takes into account severity of symptoms, previous history, duration and course of illness. Also, take into account both the degree of functional impairment and/or disability associated with the possible depression and the length of the episode. [2009, amended 2022]
Discuss with the person how the factors below may have affected the development, course and severity of their depression in addition to assessing symptoms and associated functional impairment:
any history of depression and coexisting mental health or physical disorders
any history of mood elevation (to determine if the depression may be part of bipolar disorder); see the NICE guideline on bipolar disorder
any past experience of, and response to, previous treatments
personal strengths and resources, including supportive relationships
difficulties with previous and current interpersonal relationships
current lifestyle (for example, diet, physical activity, sleep)
any recent or past experience of stressful or traumatic life events, such as redundancy, divorce, bereavement, trauma (also see the NICE guideline on post-traumatic stress disorder)
living conditions, drug (prescribed or illicit) and alcohol use, debt, employment situation, loneliness and social isolation. [2009, amended 2022]
Always ask people with depression directly about suicidal ideation and intent. If there is a risk of self-harm or suicide:
assess whether the person has adequate social support and is aware of sources of help
arrange help appropriate to the level of need
advise the person to seek further help if the situation deteriorates. [2009]
If a person with depression presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services. [2009]
Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment. Check if they have any of these symptoms and:
ensure that the person knows how to seek help promptly
review the person's treatment if they develop marked and/or prolonged agitation. [2009]
Advise a person with depression and their family or carer to be vigilant for mood changes, agitation, negativity and hopelessness, and suicidal ideation, and to contact their practitioner if concerned. This is particularly important during high-risk periods, such as starting or changing treatment and at times of increased personal stress. [2009, amended 2022]
If a person with depression is assessed to be at risk of suicide:
do not withhold treatment for depression on the basis of their suicide risk
take into account toxicity in overdose if an antidepressant is prescribed, or the person is taking other medication, and if necessary limit the amount of medicine available
consider increasing the level of support provided, such as more frequent in-person, video call or telephone contact
consider referral to specialist mental health services.
For further advice on risk assessment, see the NICE guideline on self-harm. For further advice on medication, see the recommendations on antidepressant medication for people at risk of suicide. [2009, amended 2022]
When depression is accompanied by symptoms of anxiety, which is particularly common in older people, the first priority should usually be to treat the depression. When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult NICE guidance for the relevant anxiety disorder if available and consider treating the anxiety disorder first. [2009, amended 2022]
When assessing a person with suspected depression:
be aware of any acquired cognitive impairments
if needed, consult with a relevant specialist when developing treatment plans and strategies. [2009]
When providing interventions for people with an acquired cognitive impairment who have a diagnosis of depression:
if possible, provide the same interventions as for other people with depression
if needed, adjust the method of delivery or length of the intervention to take account of the person's ability to communicate, disability or impairment.
For people with depression who also have dementia, see the section on depression and anxiety in the NICE guideline on dementia. [2009, amended 2022]
Discuss with people with depression:
what, if anything, they think might be contributing to the development of their depression (see recommendation 1.2.7 in the section on initial assessment)
whether they have ideas or preferences about starting treatment, and what treatment options they have previously found helpful or might prefer
their experience of any prior episodes of depression, or treatments for depression
what they hope to gain from treatment. [2022]
Help build a trusting relationship with the person with depression and facilitate continuity of care by:
ensuring they can see the same healthcare professional wherever possible
recording their views and preferences so that other practitioners are aware of these details. [2022]
Discuss with people with depression their preferences for treatments (including declining an offer of treatment, or changing their mind once a treatment has started) by providing:
information on what treatments are NICE-recommended, their potential benefits and harms, any waiting times for treatments, and the expected outcomes (see table 1 and table 2 on the recommended treatments for a new episode of less severe and more severe depression)
a choice of:
the treatments recommended in this guideline
how they will be delivered (for example individual or group, in person or remotely) and
where they will be delivered
the option to attend with a family member or friend when possible, for some or all of their treatment
the option to express a preference for the gender of the healthcare professional, to see a professional they already have a good relationship with, or to change professional if the relationship is not working. [2022]
Commissioners and service managers should ensure that people can express a preference for NICE-recommended treatments, that those treatments are available in a timely manner, particularly in severe depression, and that they are monitored to ensure equality of access, provision, outcomes and experience. [2022]
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on choice of treatments.
Full details of the evidence and the committee's discussion are in evidence review I: patient choice.
When considering treatments for people with depression:
carry out an assessment of need
develop a treatment plan
take into account any physical health problems
take into account any coexisting mental health problems
discuss what factors would make the person most likely to engage with treatment (including reviewing positive and negative experiences of previous treatment)
take into account previous treatment history
address any barriers to the delivery of treatments because of any disabilities, language or communication difficulties
ensure regular liaison between healthcare professionals in specialist and non-specialist settings, if the person is receiving specialist support or treatment.
For people with depression:
who also have learning disabilities, see the NICE guideline on mental health problems in people with learning disabilities.
who also have autism, see the NICE guideline on autism spectrum disorder
who also have dementia, see the NICE guideline on dementia
in pregnancy or the postnatal period, or who are breastfeeding, see the NICE guideline on antenatal and postnatal mental health
who are menopausal, see the NICE guideline on menopause
and physical health problems, see the NICE guideline on depression in adults with a chronic physical health problem and also see the recommendations on collaborative care. [2022]
Match the choice of treatment to meet the needs and preferences of the person with depression. Use the least intrusive and most resource efficient treatment that is appropriate for their clinical needs, or one that has worked for them in the past. [2022]
For all people with depression having treatment:
review how well the treatment is working with the person between 2 and 4 weeks after starting treatment
monitor and evaluate treatment concordance
monitor for side effects and harms of treatment
monitor suicidal ideation, particularly in the early weeks of treatment (see also the recommendations on antidepressant medication for people at risk of suicide and recommendations on risk assessment)
consider routine outcome monitoring (using appropriate validated sessional outcome measures, for example PHQ-9) and follow up. [2009, amended 2022]
Inform people if there are waiting lists for a course of treatment and how long the wait is likely to be (for example, the NHS constitution advises that treatment should be started within 18 weeks). Keep in touch with people at regular intervals, ensure they are aware of how to access help if their condition worsens, ensure they are made aware of who they can contact about their progress on the waiting list. Consider providing self-help materials and addressing social support issues in the interim. [2022]
Use psychological and psychosocial treatment manuals to guide the form, duration and ending of interventions. [2009, amended 2022]
Consider using competence frameworks developed from treatment manual(s) for psychological and psychosocial interventions to support the effective training, delivery and supervision of interventions. [2009]
All healthcare professionals delivering interventions for people with depression should:
receive regular clinical supervision
have their competence monitored and evaluated; this could include their supervisor reviewing video and audio recordings of their work (with patient consent). [2009, amended 2022]
When delivering psychological treatments for people with neurodevelopmental or learning disabilities, consider adapting the intervention as advised in the NICE guideline on mental health problems in people with learning disabilities. [2022]
When people are nearing the end of a course of psychological treatment, discuss ways in which they can maintain the benefits of treatment and ensure their ongoing wellness. [2022]
When offering a person medication for the treatment of depression, discuss and agree a management plan with the person. Include:
the reasons for offering medication
the choices of medication (if a number of different antidepressants are suitable)
the dose, and how the dose may need to be adjusted
the benefits, covering what improvements the person would like to see in their life and how the medication may help
the harms, covering both the possible side effects and withdrawal effects, including any side effects they would particularly like to avoid (for example, weight gain, sedation, effects on sexual function)
any concerns they have about taking or stopping the medication (also see the recommendations on stopping medication).
Make sure they have written information to take away and to review that is appropriate for their needs. [2022]
When prescribing antidepressant medication, ensure people have information about:
how they may be affected when they first start taking antidepressant medication, and what these effects might be
how long it takes to see an effect (usually, if the antidepressant medication is going to work, within 4 weeks)
when their first review will be; this will usually be within 2 weeks to check their symptoms are improving and for side effects, or 1 week after starting antidepressant medication if a new prescription is for a person aged 18 to 25 years or if there is a particular concern for risk of suicide (see the recommendations on antidepressant medication for people at risk of suicide)
the importance of following instructions on how to take antidepressant medication (for example, time of day, interactions with other medicines and alcohol)
why regular monitoring is needed, and how often they will need to attend for review
how they can self-monitor their symptoms, and how this may help them feel involved in their own recovery
that treatment might need to be taken for at least 6 months after the remission of symptoms, but should be reviewed regularly
how some side effects may persist throughout treatment
withdrawal symptoms and how these withdrawal effects can be minimised (see also the recommendations on stopping antidepressant medication). [2022]
Advise people taking antidepressant medication to talk with the person who prescribed their medication (for example, their primary healthcare or mental health professional) if they want to stop taking it. Explain that it is usually necessary to reduce the dose in stages over time (called 'tapering') but that most people stop antidepressants successfully. [2022]
Advise people taking antidepressant medication that if they stop taking it abruptly, miss doses or do not take a full dose, they may have withdrawal symptoms. Also advise them that withdrawal symptoms do not affect everyone, and can vary in type and severity between individuals. Symptoms may include:
unsteadiness, vertigo or dizziness
altered sensations (for example, electric shock sensations)
altered feelings (for example, irritability, anxiety, low mood tearfulness, panic attacks, irrational fears, confusion, or very rarely suicidal thoughts)
restlessness or agitation
problems sleeping
sweating
abdominal symptoms (for example, nausea)
palpitations, tiredness, headaches, and aches in joints and muscles. [2022]
Explain to people taking antidepressant medication that:
withdrawal symptoms can be mild, may appear within a few days of reducing or stopping antidepressant medication, and usually go away within 1 to 2 weeks
withdrawal can sometimes be more difficult, with symptoms lasting longer (in some cases several weeks, and occasionally several months)
withdrawal symptoms can sometimes be severe, particularly if the antidepressant medication is stopped suddenly. [2022]
Recognise that people may have fears and concerns about stopping their antidepressant medication (for example, the withdrawal effects they may experience, or that their depression will return) and may need support to withdraw successfully, particularly if previous attempts have led to withdrawal symptoms or have not been successful. This could include:
details of online or written resources that may be helpful
increased support from a clinician or therapist (for example, regular check-in phone calls, seeing them more frequently, providing advice about sleep hygiene). [2022]
When stopping a person's antidepressant medication:
take into account the pharmacokinetic profile (for example, the half-life of the medication as antidepressants with a short half-life will need to be tapered more slowly) and the duration of treatment
slowly reduce the dose to zero in a step-wise fashion, at each step prescribing a proportion of the previous dose (for example, 50% of previous dose)
consider using smaller reductions (for example, 25%) as the dose becomes lower
if, once very small doses have been reached, slow tapering cannot be achieved using tablets or capsules, consider using liquid preparations if available
ensure the speed and duration of withdrawal is led by and agreed with the person taking the prescribed medication, ensuring that any withdrawal symptoms have resolved or are tolerable before making the next dose reduction
take into account the broader clinical context such as the potential benefit of more rapid withdrawal if there are serious or intolerable side effects (for example, hyponatraemia or upper gastrointestinal tract bleeding)
take into account that more rapid withdrawal may be appropriate when switching antidepressants
recognise that withdrawal may take weeks or months to complete successfully. [2022]
Monitor and review people taking antidepressant medication while their dose is being reduced, both for withdrawal symptoms and the return of symptoms of depression. Base the frequency of monitoring on the person's clinical and support needs. [2022]
When reducing a person's dose of antidepressant medication, be aware that:
withdrawal symptoms can be experienced with a wide range of antidepressant medication (including tricyclic antidepressants [TCAs], selective serotonin reuptake inhibitors [SSRIs], serotonin–norepinephrine reuptake inhibitors [SNRIs], and monoamine oxidase inhibitors [MAOIs])
some commonly used antidepressants such as paroxetine and venlafaxine, are more likely to be associated with withdrawal symptoms, so particular care is needed with them
fluoxetine's prolonged duration of action means that it can sometimes be safely stopped in the following way:
in people taking 20 mg fluoxetine a day, a period of alternate day dosing can provide a suitable dose reduction
in people taking higher doses (40 mg to 60 mg fluoxetine a day), use a gradual withdrawal schedule.
allow 1 to 2 weeks to evaluate the effects of dose reduction before considering further dose reductions. [2022]
If a person has withdrawal symptoms when they stop taking antidepressant medication or reduce their dose, reassure them that they are not having a relapse of their depression. Explain that:
these symptoms are common
relapse does not usually happen as soon as you stop taking an antidepressant medication or lower the dose
even if they start taking an antidepressant medication again or increase their dose, the withdrawal symptoms may take a few days to disappear. [2022]
If a person has mild withdrawal symptoms when they stop taking antidepressant medication:
monitor their symptoms
reassure them that such symptoms are common and usually time‑limited
advise them to contact the person who prescribed their medication (for example, their primary healthcare or mental health professional) if the symptoms do not improve, or if they get worse. [2022]
If a person has more severe withdrawal symptoms, consider restarting the original antidepressant medication at the previous dose, and then attempt dose reduction at a slower rate with smaller decrements after symptoms have resolved. [2022]
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on starting and stopping antidepressants.
For full details of the evidence and the committee's discussion, see the evidence reviews for the NICE guideline on safe prescribing (evidence review A: patient information; evidence review B: prescribing strategies; evidence review C: safe withdrawal; evidence review D: withdrawal symptoms; evidence review F: monitoring).
When prescribing antidepressant medication for people with depression who are aged 18 to 25 years or are thought to be at increased risk of suicide:
assess their mental state and mood before starting the prescription, ideally in person (or by video call or by telephone call if in-person assessment is not possible, or not preferred)
be aware of the possible increased prevalence of suicidal thoughts, self-harm and suicide in the early stages of antidepressant treatment, and ensure that a risk management strategy is in place (see the section on risk assessment and management)
review them 1 week after starting the antidepressant medication or increasing the dose for suicidality (ideally in person, or by video call, or by telephone if these options are not possible or not preferred)
review them again after this as often as needed, but no later than 4 weeks after the appointment at which the antidepressant was started
base the frequency and method of ongoing review on their circumstances (for example, the availability of support, unstable housing, new life events such as bereavement, break-up of a relationship, loss of employment), and any changes in suicidal ideation or assessed risk of suicide. [2009, amended 2022]
Take into account toxicity in overdose when prescribing an antidepressant medication for people at significant risk of suicide. Do not routinely start treatment with TCAs, except lofepramine, as they are associated with the greatest risk in overdose. [2009, amended 2022]
When prescribing antidepressant medication for older people:
take into account the person's general physical health, comorbidities and possible interactions with any other medicines they may be taking
carefully monitor the person for side effects
be alert to an increased risk of falls and fractures
be alert to the risks of hyponatraemia (particularly in those with other risk factors for hyponatraemia, such as concomitant use of diuretics).
See also the NICE guideline on dementia: assessment, management and support for people living with dementia and their carers. [2009, amended 2022]
For people with depression taking lithium, assess weight, renal and thyroid function and calcium levels before treatment and then monitor at least every 6 months during treatment, or more often if there is evidence of significant renal impairment. [2009, amended 2022]
For women of reproductive age, in particular if they are planning a pregnancy, discuss the risks and benefits of lithium, preconception planning and the need for additional monitoring. [2022]
Monitor serum lithium levels 12 hours post dose, 1 week after starting treatment and 1 week after each dose change, and then weekly until levels are stable. Adjust the dose according to serum levels until the target level is reached.
when the dose is stable, monitor every 3 months for the first year
after the first year, measure plasma lithium levels every 6 months, or every 3 months for people in any of the following groups:
older people
people taking medicines that interact with lithium
people who are at risk of impaired renal or thyroid function, raised calcium levels or other complications
people who have poor symptom control
people with poor adherence
people whose last plasma lithium level was 0.8 mmol per litre or higher. [2022]
Determine the dose of lithium according to response and tolerability:
plasma lithium levels should not exceed 1.0 mmol/L (therapeutic levels for augmentation of antidepressant medication are usually at or above 0.4 mmol/L; consider levels 0.4 to 0.6 mmol/L for older people aged 65 or above)
do not start repeat prescriptions until lithium levels and renal function are stable
take into account a person's overall physical health when reviewing test results (including possible dehydration or infection)
take into account any changes to concomitant medication (for example, angiotensin-converting enzyme inhibitors, angiotensin 2 receptor blockers, diuretics and non-steroidal anti-inflammatory drugs [NSAIDs], or over-the-counter preparations) which may affect lithium levels, and seek specialist advice if necessary
monitor at each review for signs of lithium toxicity, including diarrhoea, vomiting, coarse tremor, ataxia, confusion and convulsions
seek specialist advice if there is uncertainty about the interpretation of any test results. [2022]
Manage lithium prescribing under shared care arrangements. If there are concerns about toxicity or side effects (for example, in older people or people with renal impairment), manage their lithium prescribing in conjunction with specialist secondary care services. [2022]
Consider electrocardiogram (ECG) monitoring in people taking lithium who have a high risk of, or existing, cardiovascular disease. [2009]
Provide people taking lithium with information on how to do so safely, including the NHS lithium treatment pack. [2022]
Only stop lithium in specialist mental health services, or with their advice. When stopping lithium, whenever possible reduce doses gradually over 1 to 3 months. [2022]
For a short explanation of why the committee made these consensus recommendations and how they might affect practice, see the rationale and impact section on use of lithium as augmentation.
In June 2022, use of antipsychotics for the treatment of depression was an off-label use for some antipsychotics. See NICE's information on prescribing medicines.
Before starting an antipsychotic, check the person's baseline pulse and blood pressure, weight, nutritional status, diet, level of physical activity, fasting blood glucose or HbA1c and fasting lipids. [2022]
Carry out monitoring as indicated in the summary of product characteristics for individual medicines, for people who take an antipsychotic for the treatment of their depression. This may include:
monitoring full blood count, urea and electrolytes, liver function tests and prolactin
monitoring their weight weekly for the first 6 weeks, then at 12 weeks, 1 year and annually
monitoring their fasting blood glucose or HbA1c and fasting lipids at 12 weeks, 1 year, and then annually
ECG monitoring (at baseline and when final dose is reached) for people with established cardiovascular disease or a specific cardiovascular risk (such as diagnosis of high blood pressure) and for those taking other medicines known to prolong the cardiac QT interval (for example, citalopram or escitalopram)
at each review, monitoring for adverse effects, including extrapyramidal effects (for example, tremor, parkinsonism) and prolactin-related side effects (for example, sexual or menstrual disturbances) and reducing the dose if necessary
being aware of any possible drug interactions which may increase the levels of some antipsychotics, and monitoring and adjusting doses if necessary
if there is rapid or excessive weight gain, or abnormal lipid or blood glucose levels, investigating and managing as needed. [2022]
Manage antipsychotic prescribing under shared care arrangements. [2022]
For people with depression who are taking an antipsychotic, consider at each review whether to continue the antipsychotic based on their current physical and mental health risks. [2022]
Only stop antipsychotics in specialist mental health services, or with their advice. When stopping antipsychotics, reduce doses gradually over at least 4 weeks and in proportion to the length of treatment. [2022]
For a short explanation of why the committee made these consensus recommendations and how they might affect practice, see the rationale and impact section on use of oral antipsychotics as augmentation.
Although there is evidence that St John's Wort may be of benefit in less severe depression, healthcare professionals should:
advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's Wort with other drugs
not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including hormonal contraceptives, anticoagulants and anticonvulsants). [2009]
Advise people with winter depression that follows a seasonal pattern and who wish to try light therapy in preference to antidepressant medication or psychological treatment that the evidence for the efficacy of light therapy is uncertain. [2009]
Advise people that doing any form of physical activity on a regular basis (for example, walking, jogging, swimming, dance, gardening) could help enhance their sense of wellbeing. The benefits can be greater if this activity is outdoors. [2022]
Advise people that maintaining a healthy lifestyle (for example, eating a healthy diet, not over-using alcohol, getting enough sleep) may help improve their sense of wellbeing. See the also the NHS advice on mental wellbeing. [2022]
For a short explanation of why the committee made these consensus recommendations and how they might affect practice, see the rationale and impact section on activities to help wellbeing.
In this guideline, the term less severe depression includes the traditional categories of subthreshold symptoms and mild depression.
For people with less severe depression who do not want treatment, or people who feel that their depressive symptoms are improving:
discuss the presenting problem(s) and any underlying vulnerabilities and risk factors, as well as any concerns that the person may have
make sure the person knows they can change their mind and how to seek help
provide information about the nature and course of depression
arrange a further assessment, normally within 2 to 4 weeks
make contact (with repeated attempts if necessary), if the person does not attend follow-up appointments. [2009, amended 2022]
Discuss treatment options with people with a new episode of less severe depression, and match their choice of treatment to their clinical needs and preferences:
use table 1 and the visual summary on discussing first-line treatments for less severe depression to guide and inform the conversation
take into account that all treatments in table 1 can be used as first-line treatments, but consider the least intrusive and least resource intensive treatment first (guided self-help)
reach a shared decision on a treatment choice appropriate to the person's clinical needs, taking into account their preferences (see also the recommendations on choice of treatments)
recognise that people have a right to decline treatment. [2022]
Do not routinely offer antidepressant medication as first-line treatment for less severe depression, unless that is the person's preference. [2022]
| Treatment | How is this delivered? | Key features | Other things to think about |
|---|---|---|---|
|
Guided self-help |
|
|
|
|
Group cognitive behavioural therapy (CBT) |
|
|
|
|
Group behavioural activation (BA) |
|
|
|
|
Individual CBT |
|
|
|
|
Individual BA |
|
|
|
|
Group exercise |
|
|
|
|
Group mindfulness and meditation |
|
|
|
|
Interpersonal psychotherapy (IPT) |
|
|
|
|
Selective serotonin reuptake inhibitors (SSRIs) |
|
|
|
|
Counselling |
|
|
|
|
Short-term psychodynamic psychotherapy (STPP) |
|
|
|
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on treatment for a new episode of less severe depression.
Full details of the evidence and the committee's discussion are in evidence review B: treatment of a new episode of depression.
In this guideline the term more severe depression includes the traditional categories of moderate and severe depression.
Discuss treatment options with people who have a new episode of more severe depression, and match their choice of treatment to their clinical needs and preferences:
use table 2 and the visual summary on discussing first-line treatments for more severe depression to guide and inform the conversation
take into account that all treatments in table 2 can be used as first-line treatments
reach a shared decision on a treatment choice appropriate to the person's clinical needs, taking into account their preferences (see also the recommendations on choice of treatments)
recognise that people have a right to decline treatment. [2022]
| Treatment | How is this delivered? | Key features | Other things to think about |
|---|---|---|---|
|
Combination of individual cognitive behavioural therapy (CBT) and an antidepressant |
|
|
|
|
Individual CBT |
|
|
|
|
Individual behavioural activation (BA) |
|
|
|
|
Antidepressant medication |
|
|
|
|
Individual problem-solving |
|
|
|
|
Counselling |
|
|
|
|
Short-term psychodynamic psychotherapy (STPP) |
|
|
|
|
Interpersonal psychotherapy (IPT) |
|
|
|
|
Guided self-help |
|
|
|
|
Group exercise |
|
|
|
For a short explanation of why the committee made this recommendation and how it might affect practice, see the rationale and impact section on treatment for a new episode of more severe depression.
Full details of the evidence and the committee's discussion are in evidence review B: treatment of a new episode of depression.
Consider behavioural couples therapy for people with either less severe or more severe depression who have problems in the relationship with their partner if:
the relationship problem(s) could be contributing to their depression, or
involving their partner may help in the treatment of their depression. [2022]
Deliver behavioural couples therapy for people with depression that:
follows the behavioural principles for couples therapy
provides 15 to 20 sessions over 5 to 6 months. [2009]
For a short explanation of why the committee made this recommendation and how it might affect practice, see the rationale and impact section on behavioural couples therapy.
Full details of the evidence and the committee's discussion are in evidence review B: treatment of a new episode of depression.
Discuss with people that continuation of treatment (antidepressants or psychological therapies) after full or partial remission may reduce their risk of relapse and may help them stay well. Reach a shared decision on whether or not to continue a treatment for depression based on their clinical needs and preferences. See the visual summary on preventing relapse. [2022]
Discuss with people that the likelihood of having a relapse may be increased if they have:
a history of recurrent episodes of depression, particularly if these have occurred frequently or within the last 2 years
a history of incomplete response to previous treatment, including residual symptoms
unhelpful coping styles (for example, avoidance and rumination)
a history of severe depression (including people with severe functional impairment)
other chronic physical health or mental health problems
personal, social and environmental factors that contributed to their depression (see recommendation 1.2.7 in the section on initial assessment) and that are still present (for example, relationship problems, ongoing stress, poverty, isolation, unemployment). [2022]
Discuss with people the potential risks of continuing with antidepressants long term, and how these balance against the risks of depression relapse. These include:
possible side effects, such as an increased bleeding risk or long-term effects on sexual function
difficulty stopping antidepressants. [2022]
If a person chooses not to continue antidepressant medication for relapse prevention, advise them:
how to stop their antidepressant medication (see the recommendations on stopping antidepressant medication) and
to seek help as soon as possible if the symptoms of depression return or residual symptoms worsen. [2022]
For people who have remitted from depression when treated with antidepressant medication alone, but who have been assessed as being at higher risk of relapse, consider:
continuing with their antidepressant medication to prevent relapse, maintaining the dose that led to full or partial remission, unless there is good reason to reduce it (such as side effects) or
a course of psychological therapy (group CBT or mindfulness-based cognitive therapy [MBCT]) for people who do not wish to continue on antidepressants (follow the recommendations on stopping antidepressants) or
continuing with their antidepressant medication and a course of psychological therapy (group CBT or MBCT). [2022]
For people starting group CBT or MBCT for relapse prevention, offer a course of therapy with an explicit focus on the development of relapse prevention skills and what is needed to stay well. This usually consists of 8 sessions over 2 to 3 months with the option of additional sessions in the next 12 months. [2022]
Relapse prevention components of psychological interventions may include:
reviewing what lessons and insights were learnt in therapy and what was helpful in therapy
making concrete plans to maintain progress beyond the end of therapy including plans to consolidate any changes made to stay well and to continue to practice useful strategies
identifying stressful circumstances, triggering events, warning signs (such as anxiety or poor sleep), or unhelpful behaviours (such as avoidance or rumination) that have preceded worsening of symptoms and personal or social functioning, and making detailed contingency plans of what to do if each of these re-occur
making plans for any anticipated challenging events over the next 12 months, including life changes and anniversaries of difficult events. [2022]
Discuss with people who have remitted from depression when treated with a psychological therapy alone, but who have been assessed as being at higher risk of relapse, whether they wish to continue with their psychological therapy for relapse prevention. Reach a shared decision on further treatment. [2022]
Discuss with people who have remitted from depression when treated with a combination of an antidepressant medication and psychological therapy, but who have been assessed as being at higher risk of relapse, whether they wish to continue 1 or both treatments. Reach a shared decision on further treatment. [2022]
Continue the same therapy for people who wish to stay on a psychological therapy for relapse prevention (either alone or in combination with an antidepressant), adapted by the therapist for relapse prevention. This should include at least 4 more sessions of the same treatment with a focus on a relapse prevention component (see recommendation 1.8.7) and what is needed to stay well. [2022]
Review treatment for people continuing with antidepressant medication to prevent relapse at least every 6 months. At each review:
monitor their mood using a validated rating scale (see the recommendations on delivery of treatments)
review any side effects
review any medical, personal, social or environmental factors that may affect their risk of relapse, and encourage them to access help from other agencies
discuss with them if they wish to continue treatment; if they wish to stop antidepressant treatment, see the recommendations on stopping antidepressant medication. [2022]
Reassess the risk of relapse for people who continue with psychological therapy to prevent relapse, when they are finishing the relapse prevention treatment, and assess the need for any further follow up. [2022]
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on preventing relapse.
Full details of the evidence and the committee's discussion are in evidence review C: preventing relapse.
If a person's depression has not responded at all after 4 weeks of antidepressant medication at a recognised therapeutic dose, or after 4 to 6 weeks for psychological therapy or combined medication and psychological therapy, discuss with them:
whether there are any personal, social or environmental factors or physical or other mental health conditions that might explain why the treatment is not working
whether they have had problems adhering to the treatment plan (for example, stopping or reducing medication because of side effects, or missing sessions with their therapist).
If any of these are the case, make a shared decision with the person about the best way to try and address any problems raised, including how other agencies may be able to help with these factors. See the visual summary on further-line treatment. [2022]
If a person's depression has not responded to treatment after addressing any problems raised (see recommendation 1.9.1), and allowing an adequate time for treatment changes to work, review the diagnosis and consider the possibility of alternative or comorbid conditions that may limit response to depression treatments. [2022]
Reassure the person that although treatment has not worked, other treatments can be tried, and may be effective. [2022]
If a person's depression has had no or a limited response to treatment with psychological therapy alone, and no obvious cause can be found and resolved, discuss further treatment options with the person (including what other treatments they have found helpful in the past) and make a shared decision on how to proceed based on their clinical need and preferences. Options include:
switching to an alternative psychological treatment
adding an SSRI to the psychological therapy
switching to an SSRI alone. [2022]
If a person's depression has had no or a limited response to treatment with antidepressant medication alone, and no obvious cause can be found and resolved, discuss further treatment options with the person and make a shared decision on how to proceed based on their clinical need and preferences. Options include:
adding a group exercise intervention
switching to a psychological therapy (see the section on suggested treatment options for more severe depression)
continuing antidepressant therapy by either increasing the dose or changing the drug. For example, by:
increasing the dose of the current medication (within the licensed dose range) if the medication is well tolerated; be aware that higher doses of antidepressants may not be more effective and can increase the frequency and severity of side effects; ensure follow-up and frequent monitoring of symptoms and side effects after dose increases.
switching to another medication in the same class (for example, another SSRI)
switching to a medication of a different class (for example, an SSRI, SNRI, or in secondary care a TCA or MAOI); take into account that:
switching medication may mean cross-tapering is needed; see the NICE clinical knowledge summary on switching antidepressants
switching to or from an MAOI, or from one MAOI to another, will need to take place in, or with advice from, secondary care
TCAs are dangerous in overdose, although lofepramine has the best safety profile
changing to a combination of psychological therapy (for example, CBT, interpersonal psychotherapy [IPT] or STPP) and medication.
Consider whether some of these decisions and treatments need other services to be involved (for example, specialist mental health services for advice on switching antidepressants). [2022]
If a person's depression has had no or a limited response to treatment with a combination of antidepressant medication and psychological therapy, discuss further treatment options with the person and make a shared decision on how to proceed based on their clinical need and preferences. Options include:
switching to another psychological therapy
increasing the dose or switching to another antidepressant (see recommendation 1.9.5)
adding in another medication (see recommendation 1.9.9). [2022]
Vortioxetine is recommended as an option in NICE technology appraisal guidance when there has been no or limited response to at least 2 antidepressants within the current episode. For full details, see the guidance on vortioxetine for treating major depressive episodes (TA367, 2015). [2022]
If a person whose depression has had no response or a limited response to antidepressant medication does not want to try a psychological therapy, and instead wants to try a combination of medications, explain the possible increase in their side-effect burden. [2022]
If a person with depression wants to try a combination treatment and is willing to accept the possibility of an increased side-effect burden (see recommendation 1.9.8), consider referral to a specialist mental health setting or consulting a specialist. Treatment options include:
adding an additional antidepressant medication from a different class (for example, adding mirtazapine or trazodone to an SSRI)
combining an antidepressant medication with a second-generation antipsychotic (for example, aripiprazole, olanzapine, quetiapine or risperidone) or lithium
augmenting antidepressants with electroconvulsive therapy (see the recommendations on electroconvulsive therapy for depression), lamotrigine, or triiodothyronine (liothyronine).
Be aware that some combinations of classes of antidepressants are potentially dangerous and should be avoided (for example, a SSRI, SNRI or TCA with a MAOI), and that when using an antipsychotic the effects of this on depression, including loss of interest and motivation, should be carefully reviewed.
In June 2022, this was an off-label use for some antipsychotics, lamotrigine, and triiodothyronine (liothyronine). See NICE's information on prescribing medicines. [2022]
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on further-line treatment.
Full details of the evidence and the committee's discussion are in evidence review D: further-line treatment.
Be aware that people presenting with chronic depressive symptoms may not have sought treatment for depression previously and may be unaware that they have depression. Discussions about their mood and symptoms initiated by a healthcare practitioner may help them access treatment and services. See the visual summary on treatment for chronic depression. [2022]
For people who present with chronic depressive symptoms that significantly impair personal and social functioning and who have not received previous treatment for depression, treatment options include:
CBT or
SSRIs or
SNRIs or
TCAs (be aware that TCAs are dangerous in overdose, although lofepramine has the best safety profile) or
combination therapy with CBT and either an SSRI or a TCA.
Discuss the options with the person and reach a shared decision on treatment choice, based on their clinical needs and preferences (see also the recommendations on choice of treatments). [2022]
For people with chronic depressive symptoms, offer cognitive behavioural treatment that:
has a focus on chronic depressive symptoms
covers related maintaining processes, including avoidance, rumination and interpersonal difficulties. [2022]
For people who have had, or are still receiving, treatment for depression and who present with chronic depressive symptoms, see the recommendations on further-line treatment. [2022]
If a person with chronic depressive symptoms that significantly impair personal and social functioning cannot tolerate a particular SSRI, consider treatment with an alternative SSRI. [2022]
For people with chronic depressive symptoms that significantly impair personal and social functioning, who have not responded to SSRIs or SNRIs, consider alternative medication in specialist settings, or after consulting a specialist. Take into account that switching medication may mean that an adequate wash-out period is needed, particularly when switching to or from irreversible MAOIs or moclobemide. See the NICE clinical knowledge summary on switching antidepressants. Alternatives include:
TCAs
moclobemide
irreversible MAOIs such as phenlezine
low-dose amisulpride (maximum dose of 50 mg daily, as higher doses may worsen depression and lead to side effects such as hyperprolactinaemia and QT interval prolongation).
In June 2022, this was an off-label use for amisulpride. See NICE's information on prescribing medicines. [2022]
For people with chronic depressive symptoms that significantly impair personal and social functioning, who have been assessed as likely to benefit from extra social or vocational support, consider:
befriending in combination with existing antidepressant medication or psychological therapy; this should be done by trained volunteers, typically with at least weekly contact for between 2 to 6 months
a rehabilitation programme, if their depression has led to loss of work or their withdrawing from social activities over the longer term. [2009, amended 2022]
For people with no or limited response to treatment for chronic depressive symptoms that significantly impair personal and social functioning who have not responded to the treatments recommended in the sections on further-line treatment and chronic depressive symptoms, offer a referral to specialist mental health services for advice and further treatment. See also the recommendations on collaborative care. [2022]
For people with chronic depressive symptoms that have not responded to the treatments recommended in the sections on further-line treatment and chronic depressive symptoms, and who are on long-term antidepressant medication:
review the benefits of treatment with the person
consider stopping the medication (see the recommendations on stopping antidepressants)
discuss with the person possible reasons for non-response and what other treatments and support (including from other agencies) may be helpful. [2022]
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on chronic depressive symptoms.
Full details of the evidence and the committee's discussion are in evidence review E: chronic depression.
Do not withhold treatment for depression because of a coexisting personality disorder. See the visual summary on treatment of depression with personality disorder. [2022]
For people with depression and a diagnosis of personality disorder consider a combination of antidepressant medication and a psychological treatment (for example, BA, CBT, IPT or STPP). To help people choose between these psychological treatments, see the information on them provided in table 1 and table 2. [2022]
When delivering antidepressant medication in combination with psychological treatment for people with depression and a diagnosis of personality disorder:
give the person support and encourage them to carry on with the treatment
provide the treatment in a structured, multidisciplinary setting
use a validated measure of prospective mood monitoring or a symptom checklist or chart to assess response, or any exacerbation of emotional instability
extend the duration of treatment if needed, up to a year. [2022]
For people with depression and a diagnosis of personality disorder, consider referral to a specialist personality disorder treatment programme. See the NICE guideline on borderline personality disorder for recommendations on treatment for borderline personality disorder with coexisting depression. [2022]
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on depression in people with a diagnosis of personality disorder.
Full details of the evidence and the committee's discussion are in evidence review F: depression with coexisting personality disorder.
In June 2022, use of antipsychotics for the treatment of depression was an off-label use for some antipsychotics. See NICE's information on prescribing medicines.
Offer referral to specialist mental health services for people with depression with psychotic symptoms, where the treatment should include:
a risk assessment
an assessment of needs
a programme of coordinated multidisciplinary care
access to psychological treatments, after improvement of acute psychotic symptoms.
Discuss treatment options and, for those people who have capacity, reach a shared decision based on their clinical needs and preferences. See the visual summary on treatment of psychotic depression. [2022]
Consider combination treatment for people with depression with psychotic symptoms with antidepressant medication and antipsychotic medication (for example, olanzapine or quetiapine). [2022]
If a person with depression with psychotic symptoms does not wish to take antipsychotic medication in addition to an antidepressant, then treat with an antidepressant alone. [2022]
Monitor people with depression with psychotic symptoms for treatment response (in particular for unusual thought content and hallucinations). [2022]
Consider continuing antipsychotic medication for people with depression with psychotic symptoms for a number of months after remission, if tolerated. The decision about if and when to stop antipsychotic medication should be made by, or in consultation with, specialist services. [2022]
For more advice on prescribing and monitoring antipsychotics see the recommendations on use of oral antipsychotics as augmentation and the NICE guideline on psychosis and schizophrenia in adults. [2022]
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on psychotic depression.
Full details of the evidence and the committee's discussion are in evidence review G: psychotic depression.
Consider electroconvulsive therapy (ECT) for the treatment of severe depression if:
the person chooses ECT in preference to other treatments based on their past experience of ECT and what has previously worked for them or
a rapid response is needed (for example, if the depression is life‑threatening because the person is not eating or drinking) or
other treatments have been unsuccessful (see the recommendations on further-line treatment). [2022]
Make sure people with depression who are going to have ECT are fully informed of the risks, and of the risks and benefits specific to them. Take into account:
the risks associated with a general anaesthetic
any medical comorbidities
potential adverse events, in particular cognitive impairment
if the person is older, the possible increased risk associated with ECT treatment for this age group
the risks associated with not having ECT.
Document the assessment and discussion. [2022]
Discuss the use of ECT as a treatment option with the person with depression, and reach a shared decision on its use based on their clinical needs and preferences, if they have capacity to give consent. Take into account the capacity of the person and the requirements of the Mental Health Act 2007 (if applicable), and make sure:
informed consent is given without pressure or coercion from the circumstances or clinical setting
the person is aware of their right to change their mind and withdraw consent at any time
there is strict adherence to recognised guidelines on consent, and advocates or carers are involved to help informed discussions. [2022]
If a person with depression cannot give informed consent, only give ECT if it does not conflict with a valid advance treatment decision the person made. [2022]
For people whose depression has not responded well to ECT previously, only consider a repeat trial of ECT after:
reviewing the adequacy of the previous treatment course
considering all other options
discussing the risks and benefits with the person or, if appropriate, their advocate or carer. [2022]
Clinics should only provide ECT if they:
are Electroconvulsive Therapy Accreditation Service (ECTAS) accredited
provide ECT services in accordance with ECTAS standards
submit data, including outcomes, on each course of acute and maintenance ECT they deliver as needed for the ECTAS minimum dataset.
Follow the ECT Accreditation Service Standards for Administering ECT. [2022]
Trusts which provide ECT services should ensure compliance with the ECTAS standards for administering ECT through board-level performance management. [2022]
Stop ECT treatment for a person with depression:
immediately, if the side effects outweigh the potential benefits, or
when stable remission has been achieved. [2022]
If a person's depression has responded to a course of ECT:
start (or continue) antidepressant medication or a psychological intervention to prevent relapse and to provide ongoing care for their depression (see the recommendations on preventing relapse)
consider lithium augmentation of antidepressant medication (see the recommendations on further-line treatment). [2022]
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on further-line treatment.
Full details of the evidence and the committee's discussion are in evidence review D: further-line treatment.
Esketamine nasal spray is not recommended in NICE technology appraisal guidance for treating treatment-resistant depression. For full details, see the guidance on esketamine nasal spray (TA854, 2022).
Commissioners and providers of mental health services should consider using models such as stepped care or matched care for organising the delivery of care and treatment of people with depression. See the matched care model visual summary.
Pathways should:
promote easy access to, and uptake of, the treatments covered
allow for prompt assessment of adults with depression, including assessment of severity and risk
ensure coordination and continuity of care, with agreed protocols for sharing information
support the integrated delivery of services across primary and secondary care, to ensure individuals do not fall into gaps in service provision
have clear criteria for entry to all levels of a stepped care service
have multiple entry points and ways to access the service, including self-referral
have routine collection of data on access to, uptake of and outcomes of the specific treatments in the pathway. [2022]
Commissioners and providers of mental health services for people with depression should ensure the effective delivery of treatments. This should build on the key functions of a catchment area-based community mental health service and be provided in the context of a coordinated primary and secondary care mental health service, as well as community services (for example social care, education, housing, statutory services and the voluntary and social enterprise sector). This should include:
assessment procedures
shared decision making
collaboration between professionals
delivery of pharmacological, psychological and physical (for example exercise, ECT) interventions
delivery of interventions for personal, social and environmental factors (for example, housing problems, isolation and unemployment)
care coordination
involvement of service users in design, monitoring and evaluation of services
the effective monitoring and evaluation of services. [2022]
Commissioners and providers of primary and secondary care mental health services should ensure support is in place so integrated services can be delivered by:
individual practitioners (including primary care healthcare professionals), providing treatments, support or supervision
mental health staff, for team-based treatments in primary care for the majority of people with depression
mental health specialists, providing advice, consultation and support for primary care mental health staff
specialist-based mental health teams, for people with severe and complex needs. [2022]
Commissioners and providers of mental health services should ensure pathways have the following in place for people with depression to promote access, and increased uptake and retention:
services available outside normal working hours
services provided in community-based settings, for example in a person's home, community centres, leisure centres, care homes, social centres and integrated clinics within primary care (particularly for older people)
services delivered jointly with charities or the voluntary sector
bilingual therapists or independent translators. [2022, amended 2023]
When promoting access and uptake of services, identify and address the needs of groups who may have difficulty in accessing, or face stigma or discrimination when using some or all mental health services. This may include:
men
older people
lesbian, gay, bisexual and trans people
people from black, Asian and minority ethnic communities
people with learning disabilities or acquired cognitive impairments (see the NICE guideline on mental health problems in people with learning disabilities)
people with physical or sensory disabilities, who may need reasonable adjustments to services as defined by legislation to enable this access; see the Equality Act 2010
people who have conditions which compromise their ability to communicate
people who are homeless, refugees and asylum seekers. [2022]
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on access to services.
Full details of the evidence and the committee's discussion are in evidence review H: access to services.
Consider collaborative care for people with depression, particularly older people, those with significant physical health problems or social isolation, or those with more chronic depression not responding to usual specialist care. [2022]
Collaborative care for people with depression should comprise:
patient-centred assessment and engagement
symptom measurement and monitoring
medication management (a plan for starting, reviewing and discontinuing medication)
active care planning and follow up by a designated case manager
delivery of psychological and psychosocial treatments within a structured protocol
integrated care of both physical health and mental health
joint working with primary and secondary care colleagues
involvement of other agencies that provide support
supervision of practitioners by an experienced mental health professional. [2022]
Refer people with more severe depression or chronic depressive symptoms, to specialist mental health services for coordinated multidisciplinary care if:
their depression significantly impairs personal and social functioning and
they have not benefitted from previous treatments, and either
have multiple complicating problems, for example unemployment, poor housing or financial problems or
have significant coexisting mental and physical health conditions. [2022]
Deliver multidisciplinary care plans for people with more severe depression or chronic depressive symptoms (either of which significantly impairs personal and social functioning) and multiple complicating problems, or significant coexisting conditions that:
are developed together with the person, their GP and other relevant people involved in their care (with the person's agreement), and that a copy in an appropriate format is offered to the person
set out the roles and responsibilities of all health and social care professionals involved in delivering the care
include information about 24-hour support services, and how to contact them
include a crisis plan that identifies potential crisis triggers, and strategies to manage those triggers and their consequences
are updated if there are any significant changes in the person's needs or condition
are reviewed at agreed regular intervals
include medication management (a plan for starting, reviewing and discontinuing medication). [2022]
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on collaborative care and specialist care.
Full details of the evidence and the committee's discussion are in evidence review A: service delivery.
Consider crisis resolution and home treatment (CRHT) for people with more severe depression who are at significant risk of:
suicide, in particular for those who live alone
self-harm
harm to others
self-neglect
complications in response to their treatment, for example older people with medical comorbidities. [2022]
Ensure teams providing CRHT interventions to support people with depression:
monitor and manage risk as a high-priority routine activity
establish and implement a treatment programme
ensure continuity of any treatment programme while the person is in contact with the CRHT team, and on discharge or transfer to other services when this is needed
put a crisis management plan in place before the person is discharged from the team's care. [2022]
Consider inpatient treatment for people with more severe depression who cannot be adequately supported by a CRHT team. See also the NICE guideline on mental health problems in people with learning disabilities. [2022]
Make psychological therapies recommended for the treatment of more severe depression, relapse prevention, chronic depressive symptoms and depression with a diagnosis of personality disorder available for people with depression in secondary care settings (including community and inpatient). [2022]
When providing psychological therapies for people with depression in inpatient settings:
increase the intensity and duration of the interventions
ensure that they continue to be provided effectively and promptly on discharge. [2009]
Consider using CRHT teams for people with depression having a period of inpatient care who might benefit from early discharge from hospital. [2009]
For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on crisis care, home treatment and inpatient care.
Full details of the evidence and the committee's discussion are in evidence review A: service delivery.
This section defines terms that have been used in a particular way for this guideline. For other definitions see the NICE glossary and the Think Local, Act Personal Care and Support Jargon Buster.
Cognitive impairments are neurological disorders that affect cognitive abilities (for example, learning, memory, communication and problem-solving). Acquired disorders may be because of medical conditions that affect mental function (for example, dementia, Parkinson's disease or traumatic brain injury).
An unhelpful form of coping behaviour in which a person changes their behaviour to avoid thinking about, feeling or doing difficult things. This includes putting things off, reducing activities, not tackling problems, not speaking up for oneself, distraction and using alcohol or substances to numb feelings.
People with chronic depressive symptoms includes those who continually meet criteria for the diagnosis of a major depressive episode for at least 2 years, or have persistent subthreshold symptoms for at least 2 years, or who have persistent low mood with or without concurrent episodes of major depression for at least 2 years. People with depressive symptoms may also have a number of social and personal difficulties that contribute to the maintenance of their chronic depressive symptoms.
Collaborative care requires that the service user and healthcare professional jointly identify problems and agree goals for treatments, and normally comprises:
case management which is supervised and supported by a senior mental health professional
close collaboration between primary and secondary physical health services and specialist mental health services in the delivery of services
the provision of a range of evidence-based treatments
the long-term coordination of care and follow up.
In ICD-11, depression is defined as the presence of depressed mood or diminished interest in activities occurring most of the day, nearly every day, for at least 2 weeks, accompanied by other symptoms such as:
reduced ability to concentrate and sustain attention or marked indecisiveness
beliefs of low self-worth or excessive or inappropriate guilt
hopelessness about the future
recurrent thoughts of death or suicidal ideation or evidence of attempted suicide
significantly disrupted sleep or excessive sleep
significant changes in appetite or weight
psychomotor agitation or retardation
reduced energy or fatigue
In DSM-5 depression is defined as the presence of 5 or more symptoms from a list of 9 symptoms, during the same 2-week period and where at least 1 of the symptoms is depressed mood or loss of interest or pleasure, most of the day, nearly every day. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The 9 symptoms are:
depressed mood – indicated by subjective report or observation by others
loss of interest or pleasure in almost all activities – indicated by subjective report or observation by others
significant (more than 5% in a month) unintentional weight loss or gain or decrease or increase in appetite
sleep disturbance (insomnia or hypersomnia)
psychomotor changes (agitation or retardation) severe enough to be observable by others
tiredness, fatigue, or low energy, or decreased efficiency with which routine tasks are completed
a sense of worthlessness or excessive, inappropriate, or delusional guilt (not merely self-reproach or guilt about being sick)
impaired ability to think, concentrate, or make decisions – indicated by subjective report or observation by others
recurrent thoughts of death (not just fear of dying), suicidal ideation, or suicide attempts.
In this guideline the term 'people with depression' is used. This includes people with a clinical diagnosis of depression and those who feel themselves to be experiencing depression or depressive symptoms, and recognises that people experience, describe and label their experiences of depression in very individual ways.
Less severe depression encompasses subthreshold and mild depression, and in this guideline was defined as depression scoring less than 16 on the PHQ-9 scale.
Medication management is giving a person advice on how to keep to a regimen for the use of medication (for example, how to take it, when to take it and how often). The focus in such programmes is only on the management of medication and not on other aspects of depression.
More severe depression encompasses moderate and severe depression, and in this guideline was defined as depression scoring 16 or more on the PHQ-9 scale.
Personal functioning represents the ability of an individual to effectively engage in the normal activities of everyday living and react to experiences. Social functioning is the ability to interact with other people, develop relationships and to gain from and develop these interactions.
This is a system for the monitoring of the outcomes of treatments which involves regular assessment (usually at each contact; referred to as sessional) of symptoms or personal and social functioning using a valid scale. It can inform both service user and practitioner of progress in treatment. It is often supported by computerised delivery and scoring of the measures which ensures better completion of the questionnaires and service level audit and evaluation. Alternative terms such as 'sessional outcome monitoring' or 'sessional outcomes' may also be used which emphasise that outcomes should be recorded at each contact.
Repetitive and prolonged negative thinking about the depression, feelings and symptoms, the self, problems or difficult life events and about their causes, consequences, meanings and implications (for example 'Why did this happen to me?', 'Why can I not get better?').
This is a system of delivering and monitoring treatments, so that the most effective, least intrusive and least resource intensive treatments are delivered first. Stepped care has a built in 'self-correcting' mechanism so that people who do not benefit from initial treatments can be 'stepped up' to more intensive treatments as needed. Matched care follows the principles of stepped care, but also takes into account other factors such as patient presentation, previous experience of treatment, patient choice and preferences.
See the matched care model visual summary.
Treatment manuals are based on those that were used in the trials that provided the evidence for the efficacy of treatments recommended in this guideline.